Cost–consequence analysis of (18)F-fluciclovine for the staging of recurrent prostate cancer

Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to ‘futile’ local therapies in the presence of metastatic disease. The use of (18) F-fluciclovine PET/CT may lead to better patient management. Obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Ivar S, Hathway, Joanne, Cyr, Philip, Gauden, David, Gardiner, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170335/
https://www.ncbi.nlm.nih.gov/pubmed/32341772
http://dx.doi.org/10.1080/20016689.2020.1749362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170335/
https://www.ncbi.nlm.nih.gov/pubmed/32341772
http://dx.doi.org/10.1080/20016689.2020.1749362

Ejemplares similares